Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IO Informatics Sentient Suite Expands into Precision Medicine

Published: Tuesday, December 04, 2012
Last Updated: Tuesday, December 04, 2012
Bookmark and Share
Bill Hayden to spearhead business development effort.

IO Informatics announced today IO Healthcare, an extension of the company's award winning life sciences platform, Sentient, into precision medicine applications including biomarker discovery, clinical trial optimization and decision support. By adding clinical, genomic, metabolic and proteomic information to the platform's existing repository of public resources, IO Healthcare enables the earlier application of clinical information to enhance research and development.

"Since 2003, IO has been addressing research informatics needs at pharmaceutical and biotech companies with our semantic technology platform," said Robert Stanley, IO Informatics President and Chief Executive Officer. "Now, with IO Healthcare, we directly address the challenges of taking molecular data into clinical applications to realize the promise of precision medicine.” Stanley added, "With the growing availability and decreasing cost to integrate and query data from genomics and other molecular biology and clinical applications, IO Healthcare is a natural extension for both our Sentient platform and our customers, who have been using IO in their research for many years."

The Company’s semantic framework makes it possible to apply patterns including content from patient records and phenotypic information such as gene, protein and metabolic variables relevant across all stages of research, from early stage experimentation to precision medicine.

Stanley went on to say, “We are also very happy to have Bill Hayden join us to spearhead our Healthcare effort. Bill was previously with IO from 2007-2009, where he was instrumental in creating collaborations between IO and worldwide centers of excellence.”

"I am happy to work with IO at a very exciting time for both the company and the healthcare industry. It is a time where promise becomes practice. We have heard a lot over the years of the hope of true precision medicine. With advances in science and technology, that dream is now becoming a reality. IO sits on the crest of what I believe will be a new way and approach of delivering focused treatments and cures for a variety of diseases,” said Hayden.
 
Hayden went on to say, “IO recently announced details of its partnership with the PROOF Centre of Excellence (Vancouver, BC) where they have successfully married the identification of relevant biomarkers and related data from PROOF Centre with Sentient to produce valuable Applied Semantic Knowledgebases (ASK) that will be used in the clinic to help identify and segment patients affected by major organ failure. Dr. Bruce McManus, Director of the PROOF Centre stated, “This collaborative project represents a major step forward to realizing the promise of biomarker-based screening for precision medicine and better healthcare at lower cost.” The resulting application from the IO - PROOF Centre collaboration is scheduled to be launched in the clinic in 2013.”

In addition, pharmaceutical & biotech companies can use the IO Healthcare platform to accelerate drug discovery by applying human biology earlier in the discovery process, to discover and develop predictive biomarkers, and to optimize clinical trial design and patient selection to reduce development timelines and increase the chance of successful approval for new therapies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
New Imaging Method Reveals Nanoscale Details about DNA
Enhancement to super-resolution microscopy shows orientation of individual molecules, providing a new window into DNA’s structure and dynamics.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Scoliosis Linked to Disruptions in Spinal Fluid Flow
A new study in zebrafish suggests that irregular fluid flow through the spinal column brought on by gene mutations is linked to a type of scoliosis that can affect humans during adolescence.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!